Comprehensive Immune Profiling Unveils a Subset of Leiomyosarcoma with “Hot” Tumor Immune Microenvironment

SIMPLE SUMMARY: Leiomyosarcoma (LMS) is thought to be an immune cold tumor that generally does not respond to immune checkpoint inhibitors (ICIs). To date, there is no validated immune biomarker used in LMS patients. The tertiary lymphoid structure (TLS) is the only potential predictive biomarker, b...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Xiaolan, Tonon, Laurie, Li, Haocheng, Darbo, Elodie, Pleasance, Erin, Macagno, Nicolas, Dufresne, Armelle, Brahmi, Mehdi, Bollard, Julien, Ducimetière, Francoise, Karanian, Marie, Meurgey, Alexandra, Pérot, Gaëlle, Valentin, Thibaud, Chibon, Frédéric, Blay, Jean-Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378143/
https://www.ncbi.nlm.nih.gov/pubmed/37509366
http://dx.doi.org/10.3390/cancers15143705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378143/
https://www.ncbi.nlm.nih.gov/pubmed/37509366
http://dx.doi.org/10.3390/cancers15143705

Ejemplares similares